ID
32059
Beschreibung
Study ID: 103992 Clinical Study ID: 103992 Study Title: Evaluate immunogenicity, reactogenicity & safety of 2 doses of GSK Biologicals’ oral live attenuated HRV vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00139334 https://clinicaltrials.gov/ct2/show/NCT00139334 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Rotavirus Vaccine Trade Name: Rotarix Study Indication: Haemophilus influenzae type b; Neisseria Meningitidis This form contains Contraindications to subsequent vaccination. All items need to be checked prior to any vaccination during the study (Visits 1 - 5). Visit 1 -> Timing: Day 0, Age: 6 weeks +/- 1 week Visit 2 -> Timing: Day 30, Age: 10 weeks +/- 1 week Visit 3 -> Timing: Day 45, Age: 12 weeks +/- 1 week Visit 4 -> Timing: Day 60, Age: 14 weeks +/- 1 week Visit 5 -> Timing: Day 75, Age: 16 weeks +/- 1 week
Link
https://clinicaltrials.gov/ct2/show/NCT00139334
Stichworte
Versionen (2)
- 16.10.18 16.10.18 - Sarah Riepenhausen
- 16.10.18 16.10.18 - Sarah Riepenhausen
Rechteinhaber
GlaxoSmithKline
Hochgeladen am
16. Oktober 2018
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY-NC 3.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
GSK Biologicals' oral HRV vaccine given with OPV in infants NCT00139334
Contraindications to subsequent vaccination
- StudyEvent: ODM
Beschreibung
Contraindications to subsequent Vaccination: GSK Biologicals’ OPV
Alias
- UMLS CUI-1
- C0522473
- UMLS CUI-2
- C0032375
Beschreibung
The following adverse event associated with OPV immunisation constitutes an absolute contraindication to further administration of OPV vaccine; if this adverse event occurs during the study, the subject must be withdrawn and must be followed until resolution of the event as with any adverse event:
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0020517
- UMLS CUI [1,2]
- C0027603
- UMLS CUI [2,1]
- C0020517
- UMLS CUI [2,2]
- C0042210
- UMLS CUI [2,3]
- C1705248
- UMLS CUI [3,1]
- C0332300
- UMLS CUI [3,2]
- C0027603
- UMLS CUI [3,3]
- C0011616
Beschreibung
The following adverse event associated with OPV immunisation constitutes an absolute contraindication to further administration of OPV vaccine; if this adverse event occurs during the study, the subject must be withdrawn and must be followed until resolution of the event as with any adverse event:
Datentyp
boolean
Alias
- UMLS CUI [1]
- C0398686
- UMLS CUI [2]
- C0398795
- UMLS CUI [3,1]
- C0332300
- UMLS CUI [3,2]
- C0019693
Beschreibung
Precaution
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0743842
- UMLS CUI [1,2]
- C0205082
- UMLS CUI [2]
- C0011991
- UMLS CUI [3,1]
- C0042963
- UMLS CUI [3,2]
- C0205322
Ähnliche Modelle
Contraindications to subsequent vaccination
- StudyEvent: ODM
C0597418 (UMLS CUI-2)
C0597418 (UMLS CUI [1,2])
C0489749 (UMLS CUI [2])
C0032375 (UMLS CUI-2)
C0027603 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0042210 (UMLS CUI [2,2])
C1705248 (UMLS CUI [2,3])
C0332300 (UMLS CUI [3,1])
C0027603 (UMLS CUI [3,2])
C0011616 (UMLS CUI [3,3])
C0398795 (UMLS CUI [2])
C0332300 (UMLS CUI [3,1])
C0019693 (UMLS CUI [3,2])
C0205082 (UMLS CUI [1,2])
C0011991 (UMLS CUI [2])
C0042963 (UMLS CUI [3,1])
C0205322 (UMLS CUI [3,2])